SURFACTANT METABOLISM IN PNEUMOCYSTIS CARINII PNEUMONIA
卡氏肺囊虫肺炎中的表面活性剂代谢
基本信息
- 批准号:6576606
- 负责人:
- 金额:$ 28.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-05-15 至 2003-05-14
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Despite recent advances in its diagnosis, therapy, and prophylaxis,
Pneumocystis carinii pneumonia (PCP) remains a leading cause of morbidity
and mortality in patients with the Acquired Immunodeficiency Syndrome
(AIDS). This life-threatening opportunistic infection is associated with
impaired gas exchange leading to clinically significant hypoxemia. The
disease is caused by an enigmatic pathogen whose basic biology is poorly
understood because of difficulty culturing the organism in vitro and
cumbersome animal models of the infection. Surfactant abnormalities and
pulmonary inflammation appear to have an important role in the
pathogenesis of PCP and its associated hypoxemia; however the initiating
and effector mechanisms for these events are not known. Because the
hypoxic lung injury produced by PCP is associated with abnormalities in
surfactant biophysics and lipid content, we hypothesize that: (i) severe
disruption of normal pulmonary surfactant homeostasis is induced directly
by P. carinii. The interaction of P. carinii with the distal alveolar
epithelium is mediated by an abundant, immunogenic, cell-surface protein,
glycoprotein A (gpA) found on the outer cell wall of the organism. These
events include alteration in surfactant lipid metabolism and changes in
the expression and cellular metabolism of surfactant specific proteins.
(ii) Additional indirect mechanisms mediated via TNF-alpha produced by the
host inflammatory response further disrupt surfactant homeostasis. We
propose to characterize the role of gpA in the specific interaction of
this organism with host epithelial cells and study mechanisms by which
Pneumocystis mediates the severe lung injury seen with PCP using a murine
model of infection. The specific aims are: (1) Define the cellular effects
of Pneumocystis gp-A on lung surfactant metabolism in vitro; (2)
Characterize changes in surfactant metabolism in an immunocompromised
mouse model of PCP. To accomplish these aims, we will utilize in vivo
animal systems to grow P. carinii as a source of purified gp-A and a well-
controlled model of PCP infection. The project will combine elements
derived from several thematic research programs to yield a comprehensive
investigative proposal including: 1) A Principal Investigator with
expertise in the major areas of surfactant biology; 2) a co-investigator
experiences with P. carinii biology, gpA purification and animal models of
PCP; 3) A consultant recognized as an authority on the scid mouse model of
PCP. Results from these studies will further our understanding of the
pathogenesis of P. carinii lung infection.
尽管最近在诊断、治疗和预防方面取得了进展,
卡氏肺孢子虫肺炎(PCP)仍然是发病的主要原因
艾滋病毒/艾滋病患者的死亡率
(艾滋病)。这种危及生命的机会性感染与
气体交换受损,导致临床上显著的低氧血症。的
疾病是由一种神秘的病原体引起的,
由于难以在体外培养生物体,
繁琐的感染动物模型。表面活性剂异常,
肺部炎症似乎在
PCP的发病机制及其相关的低氧血症;然而,
并且这些事件的效应器机制是未知的。因为
PCP引起的缺氧性肺损伤与
表面活性剂生物物理学和脂质含量,我们假设:(i)严重
直接引起正常肺表面活性物质稳态的破坏
P. carinii。卡氏肺孢子虫与远侧牙槽骨的相互作用
上皮由丰富的免疫原性细胞表面蛋白介导,
在生物体的细胞外壁上发现的糖蛋白A(gpA)。这些
事件包括表面活性剂脂质代谢的改变和
表面活性物质特异性蛋白的表达和细胞代谢。
(ii)通过TNF-α介导的其他间接机制,
宿主炎症反应进一步破坏了表面活性剂体内平衡。我们
建议描述gpA在特定相互作用中的作用,
这种有机体与宿主上皮细胞和研究机制,
肺孢子虫介导使用小鼠观察到的PCP严重肺损伤
感染的模式。具体目标是:(1)明确细胞效应
肺孢子虫gp-A对肺表面活性物质代谢的影响;(2)
表征免疫功能低下患者中表面活性剂代谢的变化
PCP小鼠模型。为了实现这些目标,我们将利用体内
动物系统生长卡氏肺孢子虫作为纯化gp-A的来源,
PCP感染的控制模型。该项目将结合联合收割机元素
从几个专题研究项目中得出一个全面的
研究建议包括:1)一名主要研究者,
表面活性剂生物学主要领域的专业知识; 2)共同研究者
卡氏肺孢子虫生物学、gpA纯化和动物模型的经验
PCP; 3)公认的scid小鼠模型权威顾问
五氯酚这些研究的结果将进一步加深我们对
卡氏肺孢子虫肺部感染的发病机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL FRANCIS BEERS其他文献
MICHAEL FRANCIS BEERS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL FRANCIS BEERS', 18)}}的其他基金
Surfactant Protein C Mouse Models: A Fit For Purpose Preclinical Platform For Advancing Discovery In And Treatment Of Idiopathic Pulmonary Fibrosis
表面活性剂蛋白 C 小鼠模型:一个适合目的的临床前平台,可促进特发性肺纤维化的发现和治疗
- 批准号:
10321882 - 财政年份:2021
- 资助金额:
$ 28.24万 - 项目类别:
COVID-19: Understanding The Role of Corona Virus InducedDisruption Of Alveolar Type 2 Cell Function And SurfactantHomeostasis In The Pathogenesis Of COVID-19 AcuteRespiratory Distress Syndrome
COVID-19:了解冠状病毒引起的肺泡 2 型细胞功能和表面活性剂稳态破坏在 COVID-19 急性呼吸窘迫综合征发病机制中的作用
- 批准号:
10744174 - 财政年份:2021
- 资助金额:
$ 28.24万 - 项目类别:
Surfactant Protein C Mouse Models: A Fit For Purpose Preclinical Platform For Advancing Discovery In And Treatment Of Idiopathic Pulmonary Fibrosis
表面活性剂蛋白 C 小鼠模型:一个适合目的的临床前平台,可促进特发性肺纤维化的发现和治疗
- 批准号:
10542732 - 财政年份:2021
- 资助金额:
$ 28.24万 - 项目类别:
COVID-19: Understanding The Role of Corona Virus InducedDisruption Of Alveolar Type 2 Cell Function And SurfactantHomeostasis In The Pathogenesis Of COVID-19 AcuteRespiratory Distress Syndrome
COVID-19:了解冠状病毒引起的肺泡 2 型细胞功能和表面活性剂稳态破坏在 COVID-19 急性呼吸窘迫综合征发病机制中的作用
- 批准号:
10152248 - 财政年份:2021
- 资助金额:
$ 28.24万 - 项目类别:
Surfactant Protein C Mouse Models: A Fit For Purpose Preclinical Platform For Advancing Discovery In And Treatment Of Idiopathic Pulmonary Fibrosis
表面活性剂蛋白 C 小鼠模型:一个适合目的的临床前平台,可促进特发性肺纤维化的发现和治疗
- 批准号:
10025851 - 财政年份:2021
- 资助金额:
$ 28.24万 - 项目类别:
COVID-19: Understanding The Role of Corona Virus InducedDisruption Of Alveolar Type 2 Cell Function And SurfactantHomeostasis In The Pathogenesis Of COVID-19 AcuteRespiratory Distress Syndrome
COVID-19:了解冠状病毒引起的肺泡 2 型细胞功能和表面活性剂稳态破坏在 COVID-19 急性呼吸窘迫综合征发病机制中的作用
- 批准号:
10367948 - 财政年份:2021
- 资助金额:
$ 28.24万 - 项目类别:
Alveolar Epithelial Cell Dysfunction in Pulmonary Fibrosis: Leveraging SFTPC Mutations for Discovery of Molecular and Cellular Targets
肺纤维化中的肺泡上皮细胞功能障碍:利用 SFTPC 突变发现分子和细胞靶点
- 批准号:
10165806 - 财政年份:2019
- 资助金额:
$ 28.24万 - 项目类别:
Alveolar Epithelial Cell Dysfunction in Pulmonary Fibrosis: Leveraging SFTPC Mutations for Discovery of Molecular and Cellular Targets
肺纤维化中的肺泡上皮细胞功能障碍:利用 SFTPC 突变发现分子和细胞靶点
- 批准号:
10407546 - 财政年份:2019
- 资助金额:
$ 28.24万 - 项目类别:
Biosynthesis and Trafficking of Surfactant Protein C In Health and Disease
表面活性剂蛋白 C 在健康和疾病中的生物合成和运输
- 批准号:
8559147 - 财政年份:2013
- 资助金额:
$ 28.24万 - 项目类别:
Biosynthesis and Trafficking of Surfactant Protein C In Health and Disease
表面活性剂蛋白 C 在健康和疾病中的生物合成和运输
- 批准号:
8731968 - 财政年份:2013
- 资助金额:
$ 28.24万 - 项目类别:
相似海外基金
Prevention and Treatment of Pneumocystis Pneumonia
肺孢子虫肺炎的防治
- 批准号:
10605177 - 财政年份:2020
- 资助金额:
$ 28.24万 - 项目类别:
Prevention and Treatment of Pneumocystis Pneumonia
肺孢子虫肺炎的防治
- 批准号:
10382422 - 财政年份:2020
- 资助金额:
$ 28.24万 - 项目类别:
Development of a vaccine to prevent Pneumocystis pneumonia
开发预防肺孢子虫肺炎的疫苗
- 批准号:
9906567 - 财政年份:2020
- 资助金额:
$ 28.24万 - 项目类别:
Pathogenesis of spontaneous pneumocystis pneumonia in Caspase8 and Ripk3 double deficient mice
Caspase8和Ripk3双缺陷小鼠自发性肺孢子虫肺炎的发病机制
- 批准号:
19K17650 - 财政年份:2019
- 资助金额:
$ 28.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Therapeutic antibodies to treat Pneumocystis pneumonia in a nonhuman primate model of HIV infection
在 HIV 感染的非人灵长类动物模型中治疗肺孢子虫肺炎的治疗性抗体
- 批准号:
10001636 - 财政年份:2018
- 资助金额:
$ 28.24万 - 项目类别:
Therapeutic antibodies to treat Pneumocystis pneumonia in a nonhuman primate model of HIV infection
在 HIV 感染的非人灵长类动物模型中治疗肺孢子虫肺炎的治疗性抗体
- 批准号:
9624861 - 财政年份:2018
- 资助金额:
$ 28.24万 - 项目类别:
Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia
维生素 D 作为肺孢子菌肺炎的补充疗法
- 批准号:
9063354 - 财政年份:2016
- 资助金额:
$ 28.24万 - 项目类别:
Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia
维生素 D 作为肺孢子虫肺炎的补充疗法
- 批准号:
9238656 - 财政年份:2016
- 资助金额:
$ 28.24万 - 项目类别:
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia
改进肺孢子虫肺炎的治疗和诊断
- 批准号:
10521311 - 财政年份:2016
- 资助金额:
$ 28.24万 - 项目类别:
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia
改进肺孢子虫肺炎的治疗和诊断
- 批准号:
9210593 - 财政年份:2016
- 资助金额:
$ 28.24万 - 项目类别: